Antoine Papiernik is Chairman and Managing Partner at Sofinnova Partners, which he joined in 1997.<\/p>\r\n
“Life Sciences investing is not just about recognizing good science,” Papiernik says, “it’s about people — learning how to interact with co-investors, limited partners, and entrepreneurs. Listening, discerning, negotiating, and finding common interests.”<\/p>\r\n
When you find the right people to invest in, he adds, “you can bank on them more often than you can predict how the science is going to turn out.” He looks for entrepreneurs with the nimbleness to adapt, “even if that means making a major shift from where one starts out on the journey.”<\/p>\r\n
Antoine actively invests for our Capital Funds. He has been an initial investor and active board member in a number of public companies, including Actelion, ProQR, Shockwave Medical, NovusPharma (sold to CTI), and Movetis (sold to Shire). Trade sale success stories include CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis), Ethical Oncology Science (EOS, sold to Clovis Oncology) and Recor Medical (sold to Otsuka).<\/p>\r\n
He has also invested in and is a board member of private companies Reflexion Medical, Tissium, Pi-Cardia, SafeHeal, Noema Therapeutics, May Health, Highlife and Inspirna (formerly Rgenix).<\/p>\r\n
Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. He has been selected twice for the Forbes Midas List, an annual ranking recognizing the world’s top venture capital investors. Antoine is one of the few European and life science investors to have appeared on the prestigious list.<\/p>","country":"fr","companies":[],"created_at":"2024-04-16T14:19:37.000000Z"},{"id":325,"name":"Caroline Gaynor","title":"Partner","photo":{"id":684,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/684\/Screenshot-2024-07-19-164850.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/684\/conversions\/Screenshot-2024-07-19-164850-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/684\/conversions\/Screenshot-2024-07-19-164850-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/684\/conversions\/Screenshot-2024-07-19-164850-large.webp"},"category":"investors_strategics","roles":["P"],"company_name":"Lightstone Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/cgaynor\/","biography":"
Caroline Gaynor is a Partner of Lightstone Ventures and focuses on new investments in the biopharmaceutical and medical device sectors out of the firm’s Dublin office.. She currently serves as a board director for Catamaran Bio, Parvalis Therapeutics, ProVerum, Carrick Therapeutics and FIRE-1 and as board observer for Volta Medical and Cerevance. She also previously served on the board of ALX Oncology. She is a council member of the Irish Venture Capital Association and a member of the BioInnovate Ireland Board of advisors.<\/p>","country":"ie","companies":[],"created_at":"2024-07-19T23:50:22.000000Z"},{"id":228,"name":"Nathan Harrington","title":"Managing Partner, Philips Ventures","photo":{"id":444,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/444\/nathan-harrington-philips.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/444\/conversions\/nathan-harrington-philips-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/444\/conversions\/nathan-harrington-philips-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/444\/conversions\/nathan-harrington-philips-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Philips","linkedin_profile":"https:\/\/www.linkedin.com\/in\/nateharrington\/","biography":"
Nate Harrington joined Philips in 2011 and is a Managing Partner at Philips Corporate Ventures,
responsible for its Image Guided Therapy (IGT) investments. He currently serves on over a half dozen
of the portfolio’s boards; previous director positions include Corindus Vascular Robotics (CVRS) and
Affera. He also oversees its ‘fund-of-funds’ investing.
Prior to moving to Philips Ventures in 2021, Nate was the Head of Business Development for the IGT
cluster following the acquisition of Volcano. He oversaw acquisitions of Spectranetics, Cardioprolific,
EPD, Vesper Medical and led investments in various start-ups currently in the IGT portfolio.
Prior to Philips, Nate worked 9 years at Boston Scientific Corporation (BSX) where he held various
roles in both product management for Peripheral Interventions division and business development
for the Cardiac Rhythm & Vascular group. Before BSC Nate spent 6 years in management consulting,
including 3 years at Heath Advances focused on evaluating the commercial potential of emerging
medical technology ranging from biotech and diagnostics to medical devices.
Nate received his MBA from the Yale School of Management and his BA from Brown University.<\/p>","country":"us","companies":[],"created_at":"2024-05-24T21:51:47.000000Z"},{"id":180,"name":"Murielle Thinard McLane","title":"Managing Partner","photo":{"id":659,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/659\/Murielle-Thinard-McLane-Headshot.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/659\/conversions\/Murielle-Thinard-McLane-Headshot-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/659\/conversions\/Murielle-Thinard-McLane-Headshot-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/659\/conversions\/Murielle-Thinard-McLane-Headshot-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Intuitive Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/murielle-thinard-mclane\/","biography":"
Murielle is managing partner and head of Intuitive Ventures. She joined Intuitive Ventures in 2023 and brings a depth of experience across digital health tech, digital health, diagnostics, and biotech domains to lead investments in companies that are shaping the future of minimally invasive care throughout the patient continuum.
Murielle is a seasoned operator and executive with over 20 years-experience building and scaling organizations as an investor, entrepreneur and Fortune 500 executive. She most recently served as CEO of molecular diagnostics company, Ontera, and as co-founder of Nooma Bio, a life science tools platform focused on detecting cytogenetic abnormalities. She started her foray into venture capital as an Executive in Residence for GE Healthcare Ventures where she helped launch Verana Health, the largest clinical database in medicine empowering physicians and accelerating research for patients. While there she also supported investment in Genome Medical, a telehealth provider of genomic medical insights and Arterys the first cloud based deep learning imaging software start-up to receive FDA clearance. Previously, she was a General Manager at McKesson where she oversaw multi-billion-dollar P&Ls spanning therapeutics, surgical supplies, services and data analytics and before that worked in strategy and leadership roles at both Genentech, Novartis and Optum. Passionate about bridging the gender gap in the C-Suite of venture-backed companies, she served on Springboard Enterprises' executive council for pharmaceuticals and digital health, a network dedicated to building high-growth, technology-oriented companies led by women.
Murielle is a board observer for Capstan Medical and Optellum Inc.
She holds an MBA from Wharton and an MS in Finance and the Science of Management from Universite of Lyon and started her career in financial services.<\/p>","country":"us","companies":[],"created_at":"2024-04-25T22:44:06.000000Z"},{"id":117,"name":"Gilad Glick","title":"Vice President, Venture Investments - MedTech, JJDC","photo":{"id":255,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/255\/gilad-glick-j&j.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/255\/conversions\/gilad-glick-j&j-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/255\/conversions\/gilad-glick-j&j-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/255\/conversions\/gilad-glick-j&j-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Johnson & Johnson","linkedin_profile":"https:\/\/www.linkedin.com\/in\/gilad-glick-27a6b33\/","biography":"
Experienced Global (US, Europe, Japan and Israel) Medical Device Leader with both corporate (JNJ) and startup (Biosense, ITMR) experience. Currently Chief Executive Officer of publicly listed mid size Med Tech global player. Strong sales, marketing and business development skills. Bias towards market creation and fast growth. Expert in Cardiology and Sleep medicine. Enjoy building winning teams. <\/p>","country":"il","companies":[],"created_at":"2024-04-17T18:12:34.000000Z"},{"id":250,"name":"Alan Cohen","title":"General Partner","photo":{"id":505,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/505\/Alan-Cohen.jpeg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/505\/conversions\/Alan-Cohen-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/505\/conversions\/Alan-Cohen-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/505\/conversions\/Alan-Cohen-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"DCVC","linkedin_profile":"https:\/\/www.linkedin.com\/in\/alanscohen\/","biography":"
Alan is a partner focusing on an array of AI-enabled health tech, energy, security, and enterprise opportunities transforming industries. In addition to his board roles, he works across our portfolio on product\/market fit, go-to-market strategy, and executive leadership development, and led DCVC’s successful exits at Element AI, Evolv (Nasdaq: EVLV), and Caption Health.<\/p>\r\n
Alan has been a successful entrepreneur, technology executive, and board member for over 25<\/span> years for a range of iconic companies, including DCVC-backed Illumio, Nicira (acquired by VMware), Airespace (acquired by Cisco), Cisco (where he led the $25<\/span> billion enterprise marketing and solutions organization), General Growth Properties, and IBM. He has authored over 200<\/span> articles, undertaken over 1<\/span>,000<\/span> press interviews, and delivered over 100<\/span> keynotes at industry conferences. He received a bachelor’s degree in English from SUNY Buffalo, a master’s degree in English from the University of Vermont, a master’s degree in international affairs and economics from the American University School of International Service, and an MBA from New York University.<\/p>\r\n In addition to his DCVC responsibilities, he is a member of the Advisory Committee of the Secure Community Network, a mentor at the NYU-backed Endless Frontier Lab, and an adviser to Black Women on Boards.<\/p>","country":"us","companies":[],"created_at":"2024-06-12T17:13:05.000000Z"},{"id":104,"name":"Todd Brinton","title":"Board Director, Stanford Biodesign and Co-Founder, Shockwave","photo":{"id":473,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/473\/Todd-Brinton-MD-Photo-scaled-(2).jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/473\/conversions\/Todd-Brinton-MD-Photo-scaled-(2)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/473\/conversions\/Todd-Brinton-MD-Photo-scaled-(2)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/473\/conversions\/Todd-Brinton-MD-Photo-scaled-(2)-large.webp"},"category":"investors_strategics","roles":["P","F"],"company_name":"Chief Scientific Officer, Edwards Lifesciences","linkedin_profile":"https:\/\/www.linkedin.com\/in\/todd-brinton-md-96441615\/","biography":" Champion of cardiovascular innovation, as well as a strong patient focus as a practicing clinician who joined Edwards as Corporate Vice President, Advanced Technology and Chief Scientific Officer. Deep ties to the medical technology community as a co-founder, board member and advisor to a number of start-up companies and began career as an engineer in the medical technology industry, ultimately becoming a Director of Clinical Research and Development. Prior to joining Edwards, he was an interventional cardiologist, Clinical Professor of Medicine (cardiology) and Adjunct Professor of Bioengineering at the Stanford University School of Medicine while serving as the Fellowship Director at the Stanford Byers Center for Biodesign.<\/p>","country":"us","companies":[],"created_at":"2024-04-16T14:54:09.000000Z"},{"id":178,"name":"Diana Saraceni","title":"Co-Founder & General Partner","photo":{"id":763,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/763\/diana-saraceni-2.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/763\/conversions\/diana-saraceni-2-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/763\/conversions\/diana-saraceni-2-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/763\/conversions\/diana-saraceni-2-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Panakes Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/diana-saraceni-74994\/","biography":" Over 20 years of international Venture Capital experience. I co-founded and led two of the most active pan-European Venture firms, investing in a variety of geographies and different sectors - mainly Digital, Cleantech\/Deep Tech and Healthcare\/LIfe Sciences - and generated several successful exits as trade sales or IPOs. Medical & Health Technology Innovator, Entrepreneur, Inventor, Venture Capitalist<\/span><\/p>","country":"us","companies":[],"created_at":"2024-04-16T14:22:02.000000Z"},{"id":126,"name":"Gal Noyman","title":"Partner","photo":{"id":265,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/265\/gal-noyman-lionbird.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/265\/conversions\/gal-noyman-lionbird-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/265\/conversions\/gal-noyman-lionbird-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/265\/conversions\/gal-noyman-lionbird-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"LionBird","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dr-gal-noyman-veksler-4622b939\/","biography":" Gal previously co-founded and served as CEO of NeuroLabs AI, an opioids dependence prevention platform, tackling the opioid epidemic through ongoing assessment of pain and mood symptoms at home. Gal also previously served as VP Business Development and Director of Healthcare at a multinational AI expert firm, and as an investment analyst at aMoon, the largest venture capital fund in Israel.<\/p>\r\n Gal holds a PhD in Clinical and NeuroPsychology in chronic pain (for which she was awarded the national Wolf Scholarship) and has frequently published in top tier medical journals such as Vaccine and Psychiatry.<\/p>","country":"il","companies":[],"created_at":"2024-04-17T19:13:28.000000Z"},{"id":219,"name":"Barbara Castellano","title":"Partner","photo":{"id":435,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/435\/barbara-castellano-panakes.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/435\/conversions\/barbara-castellano-panakes-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/435\/conversions\/barbara-castellano-panakes-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/435\/conversions\/barbara-castellano-panakes-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Panakes Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/barbara-castellano-6594442\/","biography":" At Panakes since 2016, Barbara brings a specific expertise in cardiovascular sector as well as a broad knowledge of the medical device sector, acquired as former Director of Clinical Affairs, Certifications, Registrations and Quality Assurance at CID SpA (now Alvimedica) and as former Director of Business Development & Global Marketing Director for the Heart Valves Business Unit at Sorin (now Livanova). She was also founder and CEO of Techwald SPA, an operational Holding Company supporting and investing in early stage Med Tech Companies.<\/p>\r\n MSC University of Perugia (Medicinal Chemistry) Executive MBA Bocconi (Milan)<\/p>","country":"it","companies":[],"created_at":"2024-05-24T21:04:25.000000Z"},{"id":230,"name":"Carissa Black","title":"Senior Director, Venture Capital","photo":{"id":446,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/446\/carissa-black-medtronic.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/446\/conversions\/carissa-black-medtronic-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/446\/conversions\/carissa-black-medtronic-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/446\/conversions\/carissa-black-medtronic-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Medtronic","linkedin_profile":"https:\/\/www.linkedin.com\/in\/clbb11\/","biography":" Carissa is the Director of Venture Capital at Medtronic. As part of the Medtronic’s ventures team, she works closely with Medtronic leadership to identify new business needs and is responsible for sourcing, recommending, and managing new investment opportunities. Since joining Medtronic Ventures in 2016, she has led and managed investments that have resulted in multiple successful exits and she currently holds board director and observation seats at several Medtronic portfolio companies.<\/p>\r\n Carissa is passionate about working with management teams and other investors to bring new innovations to market to improve patient outcomes. Before joining Medtronic Ventures, Carissa held various operating roles in strategy, business development, marketing, and research and development at Medtronic, Covidien, and Philips. She received her Ph.D. in Biomedical Engineering from Boston University and her MBA from Harvard Business School.<\/p>","country":"us","companies":[],"created_at":"2024-05-24T21:56:20.000000Z"},{"id":98,"name":"Irit Yaniv","title":"Founding Partner","photo":{"id":242,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/242\/irit-yaniv-almeda.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/242\/conversions\/irit-yaniv-almeda-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/242\/conversions\/irit-yaniv-almeda-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/242\/conversions\/irit-yaniv-almeda-large.webp"},"category":"investors_strategics","roles":["I","S"],"company_name":"Almeda Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dr-irit-yaniv-6aab985\/","biography":" Dr. Yaniv has more than 25 years of experience in the venture capital, pharmaceutical and biotech industries. As a senior manager, skilled physician, and experienced board member, she possesses a highly developed combination of leadership, decision making and business skills. Dr. Yaniv has served as partner at Accelmed since 2012. During this time she led Eximo from pre-clinical development through acquisition.<\/p>\r\n Dr. Irit Yaniv previously served as Executive Director and Chairperson of Accelmed's Innovation Hub portfolio companies. A global group of funds investing and acquiring control in HealthTech companies focused on Buyout and Non-Control transactions in commercial stage companies.<\/p>\r\n Dr. Yaniv holds an MD degree from the Ben-Gurion University and an MBA from the Recanati Business School at Tel Aviv University.<\/p>","country":"il","companies":[],"created_at":"2024-04-16T14:30:26.000000Z"},{"id":334,"name":"Prof. Rafi Beyar","title":"Co-Founder, Managing General Partner","photo":{"id":699,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/699\/rafael_beyar-alive.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/699\/conversions\/rafael_beyar-alive-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/699\/conversions\/rafael_beyar-alive-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/699\/conversions\/rafael_beyar-alive-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"ALIVE","linkedin_profile":"https:\/\/www.linkedin.com\/in\/rafaelbeyar\/","biography":" Prof Beyar, former Director and CEO of Rambam Health Care Campus (2006-2019). He is a Professor of Medicine and Biomedical Engineering at the Technion. Mano Iyer is a Partner in the Sofinnova Partners MD Start Strategy. A serial entrepreneur whose ties with Sofinnova Partners stretch back more than 15 years, he rejoined the firm in 2022.<\/p>\r\n In 2008, Mano was among the co-founders of the original MD Start team that incubated companies including CorWave and LimFlow. He also advised CoreValve, a Sofinnova Capital Strategy portfolio company, which was subsequently purchased by Medtronic for $800 million.<\/p>\r\n Mano founded ReCor Medical during his time as an Entrepreneur-in-Residence at Sofinnova Partners in 2009. He left Sofinnova in 2013 to work full-time as the Chief Operating Officer of ReCor, which was successfully sold to Otsuka Medical Devices in 2018.<\/p>\r\n Mano started his career in medical devices as an engineer at Arrow International. While at Arrow, he met Tim Lenihan. In 2001, he co-founded Contract Medical International (CMI) with Lenihan, and ran operations and engineering. CMI was acquired by Heraeus Group in 2020.<\/p>\r\n He joined Sofinnova Partners thanks to an introduction from Gerard Hascoët, whom he had also met while at Arrow. The trio (Hascoët, Lenihan, Iyer) joined forces with Antoine Papiernik and, with the backing of Sofinnova Partners, founded MD Start, which, now in its third iteration, has been fully integrated into the Sofinnova platform of strategies.<\/p>\r\n Mano holds an MBA from Stanford and a Bachelor of Science in Mechanical Engineering from the Rochester Institute of Technology.<\/p>","country":"nl","companies":[],"created_at":"2024-05-24T21:45:56.000000Z"},{"id":198,"name":"Chris Carlson","title":"General Manager and Senior Vice President, Multiport Division","photo":{"id":980,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/980\/chris-carlson-intuitive.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/980\/conversions\/chris-carlson-intuitive-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/980\/conversions\/chris-carlson-intuitive-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/980\/conversions\/chris-carlson-intuitive-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Intuitive","linkedin_profile":"https:\/\/www.linkedin.com\/in\/crcarlson\/","biography":" Hands on innovation leader specialized in robotic systems and medical devices.<\/p>","country":"us","companies":[],"created_at":"2024-05-13T22:54:12.000000Z"},{"id":258,"name":"Sascha Alilovic","title":"Managing Partner","photo":{"id":513,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/513\/sascha-alilovic-shs.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/513\/conversions\/sascha-alilovic-shs-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/513\/conversions\/sascha-alilovic-shs-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/513\/conversions\/sascha-alilovic-shs-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"SHS Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/sascha-alilovic-258bb9\/","biography":" After having spent about 20 years in transactional roles (M&A, IPOs and other capital market transactions), having experience in founding corporate finance boutiques and as well as having had managerial roles in global corporates, Sascha joined SHS in 2018. Having a computer science degree next to his finance background, he is thrilled by the opportunities of digitalization in the healthcare sector. Amongst other things, Sascha is focusing on the end of the lifecycle of SHS’s investments – the partnering of SHS’s portfolio companies with strategic acquirers. Sascha serves on several medtech and life science company boards and led SHS’s first investment outside of the German speaking regions. Sascha is also promoting the necessity and opportunities of promoting innovative medtech, being a frequent speaker at European life science investment conferences.<\/p>\r\n When it comes to soccer, Sascha is a big supporter of Germany’s best football team – at least in his perception there is no one who beats Borussia Dortmund with that. Neither his colleagues at SHS nor his neighbors in Munich would agree. When it comes to European championships, he is a bit more open minded – being a son of Croatians who moved to Germany and having a Russian wife with a Swedish passport allows him to favor quite some teams in tournaments. He is also trying to beat the odds by running every morning prior to coming to the office, no matter what time of the year it is<\/p>","country":"de","companies":[],"created_at":"2024-06-14T18:06:39.000000Z"},{"id":149,"name":"Auriel August","title":"Principal","photo":{"id":289,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/289\/auriel-august-sante.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/289\/conversions\/auriel-august-sante-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/289\/conversions\/auriel-august-sante-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/289\/conversions\/auriel-august-sante-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"SANT\u00c9","linkedin_profile":"https:\/\/www.linkedin.com\/in\/aurielaugust\/","biography":" Auriel August MD is a physician, innovator, and investor passionate about driving change in healthcare.<\/p>","country":"us","companies":[],"created_at":"2024-04-17T22:56:35.000000Z"},{"id":102,"name":"Colin Morrison","title":"Senior Director of Venture Capital","photo":{"id":237,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/237\/Colin-Morrison-Boston-Scientific-at-LSI-Investor-Event.jpeg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/237\/conversions\/Colin-Morrison-Boston-Scientific-at-LSI-Investor-Event-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/237\/conversions\/Colin-Morrison-Boston-Scientific-at-LSI-Investor-Event-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/237\/conversions\/Colin-Morrison-Boston-Scientific-at-LSI-Investor-Event-large.webp"},"category":"investors_strategics","roles":["S","I","P"],"company_name":"Boston Scientific","linkedin_profile":"https:\/\/www.linkedin.com\/in\/colin-morrison-45b55012\/","biography":" Bio coming soon.<\/p>","country":"us","companies":[],"created_at":"2024-04-16T14:47:39.000000Z"},{"id":225,"name":"Alessio Beverina","title":"Founder & Managing Partner","photo":{"id":472,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/472\/Karianne-Lindenhovius-(5).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/472\/conversions\/Karianne-Lindenhovius-(5)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/472\/conversions\/Karianne-Lindenhovius-(5)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/472\/conversions\/Karianne-Lindenhovius-(5)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Panakes Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/alessiobeverina\/","biography":" Founder of Panakes, Alessio has a deep knowledge of technological development achieved through positions in leading companies and electronic lab (STM, LETI). He has an extensive experience in the venture industry, having worked for almost 10 years at Sofinnova Partners, one of the biggest VC funds in Europe, up to Partner position. He has actively invested in several start-ups across Europe, with a key role in several success growth stories and exits, including IPOs and trade sales. He is a well-known member of the European investment landscape, often invited as speaker at many international conferences. He has also actively contributed in founding the VC HUB (Italian national VC association),where he is currently the Secretary.<\/p>\r\n MSC Politecnico Milano (Chemical Engineering) MBA ESCP EAP Kauffman Fellow 13<\/p>","country":"it","companies":[],"created_at":"2024-05-24T21:41:37.000000Z"},{"id":197,"name":"Celia Hart","title":"General Partner","photo":{"id":379,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/379\/celia-hart-supernova.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/379\/conversions\/celia-hart-supernova-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/379\/conversions\/celia-hart-supernova-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/379\/conversions\/celia-hart-supernova-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Supernova Invest","linkedin_profile":"https:\/\/www.linkedin.com\/in\/hartcelia\/","biography":" Experienced deeptech investor in Life Sciences (+15 years) with a strong operational experience in the biotech Industry (Cambridge Antibody Technology\/Medimmune) and a solid academic education (Ph.D. Chemistry\/Oxford). Strong interest in companies developping life changing products and driven by outstanding entrepreneurs.<\/p>","country":"fr","companies":[],"created_at":"2024-05-13T22:50:28.000000Z"},{"id":196,"name":"Remi Spagnol","title":"Investment Director","photo":{"id":378,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/378\/remi-spagnol-supernova.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/378\/conversions\/remi-spagnol-supernova-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/378\/conversions\/remi-spagnol-supernova-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/378\/conversions\/remi-spagnol-supernova-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Supernova Invest","linkedin_profile":"https:\/\/www.linkedin.com\/in\/remi-spagnol-0b9b555b\/","biography":" Rémi has conducted a career in different funds specializing in Life Sciences where he has been involved in numerous Late-Stage investments in France and internationally, such as Poxel, Corvidia Therapeutics and Arvelle Therapeutics. A Venture Capital investor at Omnes Capital then at Andera Partners until 2019, he was more recently a structured debt investor at IPF Partners.<\/p>\r\n Rémi graduated from the Faculty of Pharmacy, University of Paris-Saclay (PharmD) and holds a Specialized Master in Management of the Biopharmaceutical Industry from ESCP Europe (MS).<\/p>","country":"fr","companies":[],"created_at":"2024-05-13T22:48:02.000000Z"},{"id":195,"name":"Andrei Miclea","title":"Investment Analyst - Life Sciences","photo":{"id":377,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/377\/andrei-miclea-high-techgrunderfonds.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/377\/conversions\/andrei-miclea-high-techgrunderfonds-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/377\/conversions\/andrei-miclea-high-techgrunderfonds-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/377\/conversions\/andrei-miclea-high-techgrunderfonds-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"HighTech Grunderfonds","linkedin_profile":"https:\/\/www.linkedin.com\/in\/dr-andrei-miclea-ab5a5020b\/","biography":" Dr. Andrei Miclea is an Investment Analyst in the Life Sciences team. Previously, he was a strategy consultant in the Pharma & Life Sciences team of Strategy& (formerly Booz & Co) in Zurich. His background is a doctorate in medicine with several years of medical experience in the neurology department at the University Hospital of Bern and a research focus in the field of neuroimmunology. He completed his postdoctoral fellowship in translational multiple sclerosis research at Harvard Medical School \/ Brigham and Women's Hospital as a fellow of the Swiss National Science Foundation. He completed his medical studies at the Charité - Universitätsmedizin Berlin.<\/p>","country":"de","companies":[],"created_at":"2024-05-13T22:45:00.000000Z"},{"id":194,"name":"Laurent Choppe","title":"Managing Partner","photo":{"id":376,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/376\/laurent-choppe-cukierman.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/376\/conversions\/laurent-choppe-cukierman-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/376\/conversions\/laurent-choppe-cukierman-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/376\/conversions\/laurent-choppe-cukierman-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Cukierman & Co. Life Sciences","linkedin_profile":"https:\/\/www.linkedin.com\/in\/laurentchoppe\/","biography":" Laurent leads Cukierman & Co. Life Sciences since 2008 and has been involved in more than 100 medtech and biotech corporate finance transactions and advisory assignments for the Cukierman group. His team works worldwide with venture-backed and middle market companies for fund raising, licensing deals and M&A transactions as well as strategic projects for key life sciences industry players.<\/p>\r\n Laurent brings an extensive international life sciences experience in managing multifunctional teams and setting up new businesses in pharmaceuticals, medical devices, biotechnology, nutraceuticals, animal health and direct-to-consumer markets.<\/p>\r\n After a veterinary practice and a new venture experience, he worked 10 years in Schering-Plough (acquired by Merck & Co.) in marketing positions in dermatology, allergy, respiratory and animal health in France, General Manager in Israel and Vice President, Virology, Oncology and Cardiology in Canada. He then served 4 years as International General Manager at Bellus Health (ex-Neurochem, NASDAQ & TSE) focused on Alzheimer and amyloidosis).<\/p>\r\n Laurent is a board member of Catalyst Investors Club (CIC), Cell-Lipo (www.cell-lipo.com) and N.E.W.S. Navigation (www.newsnavigation.com). He is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d’Alfort, CES of Veterinary Ophthalmology and MBA from INSEAD (Fontainebleau). He is married, father of 3, grandfather of 2 and lives in Lausanne (Switzerland) and Tel Aviv (Israel).<\/p>","country":"ch","companies":[],"created_at":"2024-05-13T22:41:35.000000Z"},{"id":192,"name":"Laurianne Garcia-Ordonez","title":"VC Investor","photo":{"id":465,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/465\/Untitled-design-(3).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/465\/conversions\/Untitled-design-(3)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/465\/conversions\/Untitled-design-(3)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/465\/conversions\/Untitled-design-(3)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Cr\u00e9dit Mutuel Innovation","linkedin_profile":"https:\/\/www.linkedin.com\/in\/lauriannegarciaordonez\/","biography":" Laurianne joined the Health division of Crédit Mutuel Innovation in 2018.<\/span><\/p>\r\n She previously spent four years at Abbott Diagnostics as head of regional and then national market share development for Medical Biology Laboratories. Previously, she worked in the strategic marketing department of the CEA on medtech and biotech projects for two years.<\/span><\/p>\r\n Laurianne holds a Master of Science from Grenoble Alpes University and the International Certificate in Corporate Finance from HEC Paris, training supplemented by several experiences in neuroscience at GIN, in intellectual property at Avenium Consulting and finally in capital. risk within Supernova Invest as an analyst.<\/span><\/p>\r\n Passionate about sailing, Laurianne sails in Brittany.<\/span><\/p>","country":"fr","companies":[],"created_at":"2024-05-08T00:03:46.000000Z"},{"id":201,"name":"Andrew Pieprzyk","title":"Vice President, Strategic Development - Diagnostics, International","photo":{"id":383,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/383\/andrew-piprzyk-hologic.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/383\/conversions\/andrew-piprzyk-hologic-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/383\/conversions\/andrew-piprzyk-hologic-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/383\/conversions\/andrew-piprzyk-hologic-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Hologic","linkedin_profile":"https:\/\/www.linkedin.com\/in\/drewpieprzyk\/","biography":" With over a decade of experience working in the medical device and diagnostics industry, I've worked across a range of organizations and geographies to achieve my position as the Vice President of Strategic Development for Diagnostics at Hologic.<\/p>\r\n From starting as a sales representative to becoming a VP, I've progressed in leading organizations across North & South America, EMEA and APAC by learning new skills from a range of colleagues and global experiences over my 17+ year career and by believing that I will never stop learning.<\/p>","country":"es","companies":[],"created_at":"2024-05-13T23:04:16.000000Z"},{"id":199,"name":"Anke Cassing","title":"Principal","photo":{"id":381,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/381\/anke-cassing-high-techgrunderfonds.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/381\/conversions\/anke-cassing-high-techgrunderfonds-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/381\/conversions\/anke-cassing-high-techgrunderfonds-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/381\/conversions\/anke-cassing-high-techgrunderfonds-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"High-Tech Grunderfonds","linkedin_profile":"https:\/\/www.linkedin.com\/in\/anke-cassing-84373430\/","biography":" Bio coming soon.<\/p>","country":"de","companies":[],"created_at":"2024-05-13T22:57:42.000000Z"},{"id":221,"name":"Ittai Harel","title":"Managing General Partner","photo":{"id":471,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/471\/Karianne-Lindenhovius-(4).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/471\/conversions\/Karianne-Lindenhovius-(4)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/471\/conversions\/Karianne-Lindenhovius-(4)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/471\/conversions\/Karianne-Lindenhovius-(4)-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Pitango Venture Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ittai-harel-5605787\/","biography":" Ittai Harel is a Managing Partner at Pitango Venture Capital. His experience includes 25 years of entrepreneurship and executive roles in general management, business development, and marketing at life-science technology companies ranging from digital health, biopharma and medical devices, to diagnostics and veterinary health. Ittai has led healthcare and life-science investments at Pitango for the past 16 years, with a focus on Biopharma, Medical Devices, Diagnostics, and Digital Health. Ittai currently serves on the Board of directors of QuantHealth, ProtAI, Altesa, Homethrive, Surge Therapeutics, Connie Health,TScan(NSDQ:TCRX), Visby, Incredo, Clew Medical, Medisafe, and Vertos Medical. Before joining Pitango, Ittai was head of Corporate Development and Strategy at Nektar Therapeutics (NASDAQ: NKTR) and served as Executive Vice President at IDGene Pharmaceuticals. Prior to this, he spent seven years with IDEXX Laboratories (NASDAQ:IDXX) in several roles including Head of Business Development, Corporate Development, Strategic Planning, M&A, and as GM in Europe. Ittai holds a B.Sc. in Chemical Engineering and Biotechnology from Ben Gurion University, and an MSc\/MBA from the MIT Sloan School of Management.<\/p>","country":"il","companies":[],"created_at":"2024-05-24T21:09:57.000000Z"},{"id":223,"name":"Jeroen Siemes","title":"CFO","photo":{"id":439,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/439\/jeroen-siemes-salvia.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/439\/conversions\/jeroen-siemes-salvia-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/439\/conversions\/jeroen-siemes-salvia-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/439\/conversions\/jeroen-siemes-salvia-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Salvia BioElectronics","linkedin_profile":"https:\/\/www.linkedin.com\/in\/jeroen-siemes-9679ba29\/","biography":" Experienced finance and investment professional in the MedTech sector, with a proven track record in fundraising, (financial) strategy, due diligence, and financial analysis (including forecasting and reporting).<\/p>","country":"nl","companies":[],"created_at":"2024-05-24T21:15:00.000000Z"},{"id":222,"name":"Vivien de Tusch-Lec","title":"General Partner","photo":{"id":438,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/438\/vivien-detusch-lec-ryse.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/438\/conversions\/vivien-detusch-lec-ryse-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/438\/conversions\/vivien-detusch-lec-ryse-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/438\/conversions\/vivien-detusch-lec-ryse-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"RYSE","linkedin_profile":"https:\/\/www.linkedin.com\/in\/viviendetuschlec\/","biography":" Vivien is an investor, entrepreneur, and has had 3 exits as a start-up founder (Infinancials, Bubele, Martialfunk). She ran the Tech, Media, Telecom unit for B2B Marketplace Gerson Lehman Group - and has been supporting the Investment Committee at RYSE. In 2018, she was a co-investor during the first investment programme with DigitalHealth.London<\/p>\r\n and MedCity, in Skin Analytics and LiveSmart, and now manages a portfolio of technology investments.<\/p>\r\n Vivien loves operating in start-ups, is an advisor to Loyal VC, a former journalist, and non-exec director at Techspert.io. She holds a Masters degree from the University of Cambridge and an MBA from INSEAD.<\/p>","country":"gb","companies":[],"created_at":"2024-05-24T21:12:47.000000Z"},{"id":218,"name":"Margherita Marchetti","title":"Investment Manager","photo":{"id":434,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/434\/margherita-marchetti-innovationindustries.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/434\/conversions\/margherita-marchetti-innovationindustries-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/434\/conversions\/margherita-marchetti-innovationindustries-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/434\/conversions\/margherita-marchetti-innovationindustries-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Innovation Industries","linkedin_profile":"https:\/\/www.linkedin.com\/in\/margherita-marchetti-phd-322124143\/","biography":" Margherita joined Innovation Industries in 2019, focusing on med-tech and agrifood-tech investments of the main Fund, as well as of the Medtech TTT Fund. With her academic expertise in researching life processes at the nanoscale and implementing scientific instruments for biophysical experiments and their commercialization, she brings in depth expertise in the bio- and medical sectors. Prior to joining Innovation Industries, Margherita graduated cum laude in Physics at La Sapienza University in Rome and completed her master thesis at the Vrije Universiteit Amsterdam, where she obtained a PhD in Biophysics.<\/p>","country":"nl","companies":[],"created_at":"2024-05-24T21:01:28.000000Z"},{"id":217,"name":"Caaj Greebe","title":"Partner","photo":{"id":433,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/433\/caaj-greebe-innovationindustries.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/433\/conversions\/caaj-greebe-innovationindustries-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/433\/conversions\/caaj-greebe-innovationindustries-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/433\/conversions\/caaj-greebe-innovationindustries-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Innovation Industries","linkedin_profile":"https:\/\/www.linkedin.com\/in\/caaj-greebe-3bb19420\/","biography":" Caaj started his career in investment banking in 2011 at ABN AMRO. Before joining Innovation Industries, he held the position of Vice President in the Life Sciences & Healthcare Corporate Finance team of Kempen, a pan-European boutique corporate bank headquartered in Amsterdam. During his tenure he was involved in origination and execution of M&A, capital markets and other financing transactions mainly focused on the life sciences & healthcare, consumer and agriculture sectors. Caaj has a Master degree in Molecular Biology of Utrecht University.<\/p>","country":"nl","companies":[],"created_at":"2024-05-24T20:59:14.000000Z"},{"id":216,"name":"Manfred Newrly","title":"Senior Sector Engineer","photo":{"id":765,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/765\/1556204518450.jpeg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/765\/conversions\/1556204518450-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/765\/conversions\/1556204518450-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/765\/conversions\/1556204518450-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"European Investment Bank (EIB)","linkedin_profile":"https:\/\/www.linkedin.com\/in\/manfred-newrly-03abb93\/","biography":" Bio coming soon.<\/p>","country":"be","companies":[],"created_at":"2024-05-24T20:56:36.000000Z"},{"id":215,"name":"Pablo Prieto","title":"Managing Director","photo":{"id":431,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/431\/pablo-prieto-cghealth.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/431\/conversions\/pablo-prieto-cghealth-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/431\/conversions\/pablo-prieto-cghealth-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/431\/conversions\/pablo-prieto-cghealth-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"CG Health Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/pabloprietogimenez\/","biography":" A start-up mind with experience in pharmaceuticals and consulting, my experience focuses on profiling products and market and building teams to develop and commercialize innovative products where needed most. My major in graduate school is biotechnology and my focus was drug delivery system by using biology. After my master course, I entered pharmaceutical company in Japan as a formulation scientist in 2013. My main work was formulation of peptide\/protein. I also have experience to develop oral formulation, especially solid dispersion.<\/p>","country":"jp","companies":[],"created_at":"2024-05-24T20:50:44.000000Z"},{"id":213,"name":"John Brumfield","title":"Global Vice President Marketing - CRM","photo":{"id":429,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/429\/john-brumfield-biotronik.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/429\/conversions\/john-brumfield-biotronik-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/429\/conversions\/john-brumfield-biotronik-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/429\/conversions\/john-brumfield-biotronik-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"BIOTRONIK","linkedin_profile":"https:\/\/www.linkedin.com\/in\/johnbrumfield\/","biography":" John Brumfield has a diverse work experience in the medical industry. John currently holds the position of Global Vice President Marketing - CRM at BIOTRONIK since April 2023. Prior to that, they were the Vice President of Business Management CRM at BIOTRONIK from January 2022 to April 2023. Before joining BIOTRONIK, John worked at Abbott as the Global Director of Corporate Strategy - Heart Failure from January 2018 to December 2021. John also has experience at St. Jude Medical, where they held various roles such as Sr. Manager - Global Marketing Heart Failure Portfolio, Senior Manager - Global Product Marketing - CardioMEMS, Manager - Product Marketing, Sales Representative, and Technical Service Specialist. Additionally, John co-founded Zenda Technologies and served as the Program Manager & Clinical Coordinator from January 2004 to July 2014.<\/p>\r\n <\/p>\r\n John Brumfield earned a Bachelor of Science degree in Biomedical Engineering from Georgia Institute of Technology in 2001-2005. John went on to pursue an MBA in Entrepreneurship from the same institution from 2009-2012. Later, in 2013-2014, they attended Stanford University for an Advanced Project Management Program.<\/p>","country":"de","companies":[],"created_at":"2024-05-24T20:44:52.000000Z"},{"id":224,"name":"Soyoung Park","title":"Venture Partner","photo":{"id":440,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/440\/soyoung-park-vuventure.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/440\/conversions\/soyoung-park-vuventure-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/440\/conversions\/soyoung-park-vuventure-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/440\/conversions\/soyoung-park-vuventure-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"VU Venture Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/soyoung-park-mba\/","biography":" My passion is to help founders achieve their vision and positively impact the world by identifying, evaluating, and accelerating promising startups that can create and execute first-in-class solutions. I leverage my healthcare innovation, financial analysis, and business development expertise to invest in and support entrepreneurs in solving the most pressing challenges. I also mentor aspiring entrepreneurs through various organizations, specializing in managing early-stage startup strategies and executing profit maximization projects. My ultimate goal is to improve human well-being and quality of life through venture capital and mentoring.<\/p>","country":"us","companies":[],"created_at":"2024-05-24T21:31:03.000000Z"},{"id":227,"name":"Esther Reynal de saint-Michel Richardot","title":"Founding General Partner","photo":{"id":443,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/443\/esther-reynaldesaint-michel-thena.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/443\/conversions\/esther-reynaldesaint-michel-thena-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/443\/conversions\/esther-reynaldesaint-michel-thena-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/443\/conversions\/esther-reynaldesaint-michel-thena-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"THENA Capital","linkedin_profile":"https:\/\/www.linkedin.com\/in\/esther-richardot-reynal-de-st-michel\/","biography":" As an investor and business-outcomes focused professional with over 12 years of experience in consumer insight and growth strategy consulting, I have a strong track record as a trusted advisor to large brands and investing in and mentoring start-ups in the healthtech space. My wide ranging engineering experience as a mechanical component engineer on NASA's Space Shuttle Program and beyond have improved my ability to understand my clients' technology and needs, obtain the broadest scope of protection available for my clients' mechanical and medical device inventions, and improve my clients' competitive positions in their industries. My practice includes obtaining high value patents. I have procured patents that have been litigated and were a basis of successful outcomes for my clients. I have also been instrumental in developing strategic patent portfolios for startup companies to secure funding rounds. Venture Builder in the healthtech industry, bringing early stage innovation to the patient by founding startups. Background in genetic engineering, cell and molecular biology. Experience in strategy consulting and venture capital. Passionate about innovation, sustainable impact, tech solutions.<\/p>","country":"nl","companies":[],"created_at":"2024-06-03T18:27:59.000000Z"},{"id":234,"name":"Ken Nelson","title":"Partner","photo":{"id":514,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/514\/Untitled-design-(5).png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/514\/conversions\/Untitled-design-(5)-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/514\/conversions\/Untitled-design-(5)-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/514\/conversions\/Untitled-design-(5)-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"MedTech Advantage","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ken-nelson-56aaa34\/","biography":" Over the past 10 years, I have led commercial efforts for disruptive technologies in the digital health, wearables, and cardiac remote patient monitoring industries, playing a significant role in building the teams and cultures for 3 of the top 4 market share players, including #1 (BioTelemetry), #2 (iRhythm), and #4 (Bardy Diagnostics)<\/p>","country":"us","companies":[],"created_at":"2024-06-03T18:24:49.000000Z"},{"id":237,"name":"Pieter Wijffels","title":"Venture Partner","photo":{"id":478,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/478\/peter-wijffels-nlc.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/478\/conversions\/peter-wijffels-nlc-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/478\/conversions\/peter-wijffels-nlc-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/478\/conversions\/peter-wijffels-nlc-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"NLC Health Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/wijffels\/","biography":" Pieter Wijffels is a venture partner at NLC. Prior to this, they were the head of marketing at TPV and Philips. Pieter has also worked as a project manager at Boer & Croon and as an intern at Sara Lee.<\/p>","country":"nl","companies":[],"created_at":"2024-06-03T18:33:54.000000Z"},{"id":236,"name":"Omid Akhavan","title":"Managing Director & Founder","photo":{"id":477,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/477\/omid-akhavan-anthro.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/477\/conversions\/omid-akhavan-anthro-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/477\/conversions\/omid-akhavan-anthro-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/477\/conversions\/omid-akhavan-anthro-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Anthro Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/martinomidakhavan\/","biography":" Investing across healthcare companies with a network of funds, family offices and HNWs. Amir is a medtech executive passionate about creating disruptive solutions to the biggest challenges in healthcare by leveraging advancements in medical devices, computer vision, and artificial intelligence. Most recently, he was the CEO & co-Founder of Spine Align. Amir led the development of a breakthrough platform that measures biomechanical outcomes in real-time during spinal surgery. He drove the company’s technology from initial concept to multiple advanced product offerings, and the commercial growth from both grant and investor equity fundraising to finally an acquisition to one of the largest public medical device companies in the orthopedic industry.<\/p>\r\n Amir is leading Solardis Ventures by leveraging his expertise as both a medtech executive and technologist to find the most differentiated startups in the market. By bringing together his extensive network of fellow entrepreneurs in a variety of medtech spaces, and paired with his intensive due diligence process, Amir delivers exceptional deal flow to Solardis investors. Lastly, as a fellow entrepreneur that has been on both sides of the table, Amir has a keen eye for finding the right team and is passionate about mentoring entrepreneurs towards success, and not just offering a simple check.<\/p>","country":"us","companies":[],"created_at":"2024-06-03T18:37:49.000000Z"},{"id":241,"name":"Michael Wasserman","title":"Partner and Chief Operating Officer","photo":{"id":484,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/484\/michael-wasserman-elevage.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/484\/conversions\/michael-wasserman-elevage-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/484\/conversions\/michael-wasserman-elevage-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/484\/conversions\/michael-wasserman-elevage-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Elevage Medical Technologies","linkedin_profile":"https:\/\/www.linkedin.com\/in\/michael-wasserman-a507493\/","biography":" Michael Wasserman, Ph.D. is a Partner and COO of Elevage. Michael has over 30 years of experience in healthcare as a scientist, entrepreneur, executive, and investor. Prior to Elevage, Michael served as Managing Partner of Maverix Private Equity. Michael spent 17 years at H.I.G. Capital, a diversified private equity firm with over $60 billion in assets. As a Managing Director of H.I.G.’s BioHealth platform, Michael\u202fsourced, executed, and managed a diverse investment portfolio of healthcare business across stages, sectors and geographies. Michael worked closely with management teams and portfolio companies in key areas such as R&D, product development, market access, commercial and corporate strategy, equity and debt financing and achieving liquidity through M&A or IPO. Michael has served on the boards of numerous growth stage business including HyperBranch Medical Technologies (Stryker), NeuWave Medical (Johnson & Johnson), VertiFlex (Boston Scientific), amongst others.<\/p>\r\n Michael has also founded, held prominent operating roles, and sold several private healthcare businesses. Earlier in his career, Michael worked directly for, or as a consultant to, emerging technology businesses, and in the corporate finance, pharmaceutical and clinical research industries.<\/p>\r\n Michael is a member of the Board of Trustees for the Holland Bloorview Kids Rehabilitation Hospital. He is also on the Board of Toronto Innovation Acceleration Partners (TIAP), where he chairs the Investment Committee, the Board of ORT Canada, the Faculty of Science Advisory Board at McGill University, and is a Member of The Board of Trustees Research Committee at The Center for Addiction and Mental Health.<\/p>\r\n Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology and Neuroscience from the University of Toronto.<\/p>","country":"ca","companies":[],"created_at":"2024-06-06T16:24:49.000000Z"},{"id":257,"name":"Nicole J. Walker","title":"Healthcare Innovator, Board Director, Venture Investor & Advisor","photo":{"id":512,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/512\/nicole-j-walker.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/512\/conversions\/nicole-j-walker-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/512\/conversions\/nicole-j-walker-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/512\/conversions\/nicole-j-walker-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Multiple Companies","linkedin_profile":"https:\/\/www.linkedin.com\/in\/nicole-j-walker\/","biography":" Nicole is a Healthcare Innovator & Connector, Board Director, Family-Senior Care advocate, and a former Managing Partner with Arboretum Ventures, Baird Capital, Abbott Biotech Ventures. Guy joined Astorg in 2022 following an internship and is a member of the Investment Team. Prior to joining Lauxera Capital Partners, Charles Cornevin was a Senior Associate at Eurazeo where he focused on healthcare buyouts. Charles joined Eurazeo in 2017 as an Analyst after several experiences in M&A and Private Equity (Rothschild and Hudson Advisors \/ Lone Star Funds in Munich, Dublin and London).<\/p>\r\n Charles started his career as a generalist investor within the Eurazeo Mid-Cap team and has participated in the monitoring of the following investments: Odealim (incl. exit), Redspher, Dessange, and the Rosa Group. He then launched the Eurazeo Healthcare-dedicated strategy from scratch and completed two investments in 2021: Novair Group and PSIH.<\/p>\r\n Charles graduated from Paris Dauphine University with a Masters in Corporate Finance and Financial Engineering.<\/p>","country":"fr","companies":[],"created_at":"2024-06-13T22:53:54.000000Z"},{"id":253,"name":"Samuel Levy","title":"Founding Partner","photo":{"id":508,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/508\/samuel-levy-lauxera.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/508\/conversions\/samuel-levy-lauxera-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/508\/conversions\/samuel-levy-lauxera-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/508\/conversions\/samuel-levy-lauxera-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Lauxera Capital Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/samuel-levy-543b001\/","biography":" I invest in commercial-stage health technology businesses at Lauxera Capital Partners, a firm I created in 2020. Previously, I co-founded Allurion Technologies during my second year of medical school. Over ten years, along with my partners, I built a fully-integrated, global medical device company from the idea stage through commercialization in more than 30 countries. I started my career as a member of McKinsey and Company's New York Office and Pharmaceutical and Medical Products Practice.<\/p>","country":"fr","companies":[],"created_at":"2024-06-13T22:51:23.000000Z"},{"id":193,"name":"Andrew Cleeland","title":"CEO","photo":{"id":362,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/362\/andrew-cleeland-fogarty.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/362\/conversions\/andrew-cleeland-fogarty-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/362\/conversions\/andrew-cleeland-fogarty-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/362\/conversions\/andrew-cleeland-fogarty-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Fogarty Innovation","linkedin_profile":"https:\/\/www.linkedin.com\/in\/andrew-cleeland-7024a44\/","biography":" Andrew is a seasoned executive with over 30 years experience in the medical device industry. During this time, he has held key leadership positions in organizations ranging from early-stage startups to large multinationals. In joining Fogarty Innovation he further broadens this range of experience to include managing a nonprofit. The versatility required to be effective across such diverse groups is rare and is a testament to Andrew’s strong leadership skills.<\/p>\r\n A native Australian who grew up in a suburb of Melbourne, Andrew’s leadership capabilities became evident at an early age. Raised by a single parent, Andrew was forced to grow up quickly and play a supportive role for his mother and brother. These early experiences were formative in shaping the person Andrew would become and the things he would inevitably accomplish.<\/p>\r\n Andrew’s values and life philosophy were also greatly influenced by sport. His natural athleticism and leadership propelled him into many team captain roles and ultimately competing in Australian Rules Football at a semi-professional level. If you’ve never seen this sport played, do so. It won’t take long to recognize the toughness, teamwork and grit the sport demands, all traits which Andrew continues to bring to every position he holds.<\/p>\r\n After completing his undergraduate degree, Andrew began his medtech career working for the Australian Therapeutic Goods Administration. This provided an invaluable introduction to the industry along with an appreciation for the challenges regulators face when balancing innovation with protecting public health. Several years into this role, serendipity presented him with a unique opportunity to work for a company based in the United States. Although he had never lived outside Australia, he saw it as a great opportunity and moved alone to Denver, Colorado, to work for Telectronics. He probably didn’t realize it at the time, but this move exemplifies a classic element of Andrew’s personal and professional mindset: think big, set audacious goals and act boldly. At the time, Andrew expected this to be a two-year position. Thirty years later, he’s still in the U.S., setting and achieving big goals.<\/p>\r\n Andrew’s rapid career advancement during this timeframe has been impressive. After Telectronics, he accepted a management role at Baxter Healthcare’s Novacor division, and later as vice president of Clinical and Regulatory Affairs at Bay Area startup company Radiant Medical. Following this, he was CEO of Ardian, which pioneered the use of renal denervation to treat hypertension. Ardian was acquired by Medtronic in 2011 in a transaction valued at over $1.3B which, at the time, was the largest medical device acquisition ever for a pre-revenue medical device company.<\/p>\r\n Whenever a first time CEO has such a wildly successful exit, the market often wonders: Is the person really that good or were they just lucky? Andrew quickly answered that question by taking the role of CEO at Twelve, a startup in the transcatheter mitral valve space. Several years after his joining, this company was also acquired by Medtronic in a transaction valued at $458M. Back to back successes at such large valuations answered the question – it wasn’t just luck.<\/p>\r\n Propelled by these successes, Andrew has become a key figure in the medical device community. His leadership, experience and insights have led many organizations to seek his involvement. He currently serves on the board of three venture-funded companies — Saluda Medical, Zenflow, Inc. (chairman) and MMI S.p.A. (chairman). He also holds advisory positions at two top-tier venture capital firms: Longitude Capital and Arboretum Ventures. At a global industry level, he has been invited to serve on multiple initiatives including the UCSF-Stanford Pediatric Device Consortium; the Medical Device Innovation Consortium; and the Singapore government’s Biomedical Research Council (BMRC).<\/p>\r\n Passionate about healthcare, Andrew is a champion of innovators and innovation in the medtech field. His commitment to mentoring and education is rooted in his passion for helping patients and being a catalyst for positive change. This purpose and drive is captured in one of his favorite quotes, by Mahatma Gandhi: “A small body of determined spirits fired by an unquenchable faith in their mission can alter the course of history.”<\/p>\r\n “Working at Fogarty Innovation gives me the ability to positively influence the medtech ecosystem and give back in a meaningful and effective way,” summarizes Andrew. “To have worked with such amazing teammates on such impactful programs has allowed me to do something BOTH meaningful and enjoyable…I love the challenge.”<\/p>\r\n Andrew has received numerous awards and honors and is a frequent invited lecturer at major industry conferences and leading academic institutions. Andrew holds a BS in biophysics from the Swinburne Institute of Technology.<\/p>","country":"us","companies":[],"created_at":"2024-05-09T23:32:41.000000Z"},{"id":141,"name":"Ehsan Jabbarzadeh","title":"Venture Partner","photo":{"id":280,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/280\/ehsan-jabbarzadeh-iag.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/280\/conversions\/ehsan-jabbarzadeh-iag-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/280\/conversions\/ehsan-jabbarzadeh-iag-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/280\/conversions\/ehsan-jabbarzadeh-iag-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"IAG Capital Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/ehsanjabbarzadeh\/","biography":" Ehsan is an academic entrepreneur turned investor. A Ph.D. graduate from Drexel University’s Chemical and Biological Engineering, he stumbled into entrepreneurship during his postdoc at the California Institute of Technology. Upon starting his career at the University of South Carolina as a Professor, he led his lab to focus on translational research in biomedical engineering. He concurrently pursued an MBA in Finance and Entrepreneurship at the University of Southern California, Marshall School of Business, to strengthen his business acumen. Ehsan was the Founder and CEO of Obsidio Inc, a venture-backed medical device company dedicated to developing innovative technologies for interventional medicine. Obsidio was launched in 2019 and acquired by Boston Scientific in 2022.<\/p>","country":"us","companies":[],"created_at":"2024-04-17T22:14:35.000000Z"},{"id":142,"name":"Zhong Lin","title":"Partner","photo":{"id":409,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/409\/Screenshot-2024-05-20-at-2.38.38\u202fPM.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/409\/conversions\/Screenshot-2024-05-20-at-2.38.38\u202fPM-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/409\/conversions\/Screenshot-2024-05-20-at-2.38.38\u202fPM-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/409\/conversions\/Screenshot-2024-05-20-at-2.38.38\u202fPM-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Mednovation","linkedin_profile":"https:\/\/www.linkedin.com\/in\/zhong-lin-5660b047\/","biography":"
Chairwoman of several national and international selection committees and juries for start-up contests including Premio Marzotto (on all editions since 2014) and European Health-tech Summit (2018); repeatedly member of Horizon 2020 final selection committees; US National Cancer Institute, 2020 and 2021 member of NCI Investor Initiatives Review Committee
Speaker at European\/US conferences on Entrepreneurship, Innovation and Life Sciences investment trends<\/p>","country":"it","companies":[],"created_at":"2024-04-25T22:35:10.000000Z"},{"id":95,"name":"Josh Makower","title":"Director & Co-Founder, Stanford Byers Center for Biodesign","photo":{"id":230,"mime_type":"image\/png","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/230\/Josh-Makower-Headshot.png","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/230\/conversions\/Josh-Makower-Headshot-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/230\/conversions\/Josh-Makower-Headshot-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/230\/conversions\/Josh-Makower-Headshot-large.webp"},"category":"investors_strategics","roles":["F","I","P"],"company_name":"Venture Partner, Sofinnova Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/josh-makower\/","biography":"
He received an MD from Tel Aviv University, DSc in Biomedical Engineering from the Technion, and MPH from the Bloomberg School of Public Health, Johns Hopkins University.
He served as Dean of the Rappaport Faculty of Medicine (1999-2004), establishing the Johns Hopkins Technion-Collaboration Program.
Prof. Beyar led the hospital through an unprecedented development of the Rambam Comprehensive West campus, combining education, research, and innovation. This included the 2,000-bed Fortified Underground Emergency Hospital, the Children’s Hospital and the Oncology Center. He also initiated the planning and construction of the Heart Hospital and Helmsley Health Discovery Tower, a hybrid for clinical, academic, and industrial collaborations.
Beyar also established the Tech-transfer company- Rambam MedTech, and spearheaded the hospital's role for establishment of the MindUp Incubator on Digital Health. Among his national posts, Beyar was chair of the Israeli Basket committee (2010-2014) and serves as the Chair of the Steering committee for the Israeli Organ Transplant Center.
Beyar is a practicing interventional cardiologist, innovative researcher, inventor, and entrepreneur, co-authored more than 300 publications and 15 books, is the recipient of numerous awards such as the Johns Hopkins Society of Scholars Award (2005) and an Honorary Doctorate from University of Haifa (2018).
Beyar co-founded InStent (1989) sold to Medtronic (1996) and founded NaviCath (Later Corindus), a Technion Incubator Company (2002) who developed the world’s first robotic coronary intervention, sold to Siemens Healthineers (2019). He founded and co-chairs with Prof Chaim Lotan the world leading meeting on Innovation in Cardiovascular Interventions meeting (ICI) since 1996.<\/p>","country":"il","companies":[],"created_at":"2024-07-24T17:22:33.000000Z"},{"id":226,"name":"Mano Iyer","title":"Partner","photo":{"id":442,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/442\/mano-iyer-sofinnova.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/442\/conversions\/mano-iyer-sofinnova-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/442\/conversions\/mano-iyer-sofinnova-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/442\/conversions\/mano-iyer-sofinnova-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Sofinnova Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/mano-iyer-0bb6b8\/","biography":"
I am a blend of science trained professional and business experience person, very interested in how digital health is integrating in the healthcare ecosystem with an increasingly empowered, more connected patient \/ user.
Connect with me if you like exchanging thoughts and ideas about healthcare, I am always game for a good chat, or if you want to engage in advisory services.<\/p>","country":"es","companies":[],"created_at":"2024-05-24T20:52:39.000000Z"},{"id":214,"name":"Kohei Miayabe","title":"Manager","photo":{"id":430,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/430\/kohei-miyabe-asahi.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/430\/conversions\/kohei-miyabe-asahi-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/430\/conversions\/kohei-miyabe-asahi-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/430\/conversions\/kohei-miyabe-asahi-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Asahi Kasei","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kohei-miyabe-66b4a0163\/","biography":"
My passion lies in scaling-up and supporting companies seeking to transform the lives of patients, consumers, and HCPs, driving impact, problem solving, and building effective strategies.<\/p>","country":"gb","companies":[],"created_at":"2024-05-24T21:49:07.000000Z"},{"id":252,"name":"Kregg Koch","title":"Partner","photo":{"id":507,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/507\/kregg-koch-knobbe.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/507\/conversions\/kregg-koch-knobbe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/507\/conversions\/kregg-koch-knobbe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/507\/conversions\/kregg-koch-knobbe-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Knobbe Martens","linkedin_profile":"https:\/\/www.linkedin.com\/in\/kregg-koch\/","biography":"
While working on NASA's Space Shuttle Program, I received NASA’s Space Flight Awareness Award for engine safety related contributions.
Additionally, I was named as one of Southern California’s “Rising Stars” in intellectual property law in 2009 and 2010 in a survey of my peers published in Super Lawyers magazine.<\/p>","country":"us","companies":[],"created_at":"2024-06-13T17:53:53.000000Z"},{"id":251,"name":"Harnik Shukla","title":"Partner","photo":{"id":506,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/506\/harnik-shukla-knobbe.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/506\/conversions\/harnik-shukla-knobbe-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/506\/conversions\/harnik-shukla-knobbe-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/506\/conversions\/harnik-shukla-knobbe-large.webp"},"category":"investors_strategics","roles":["S"],"company_name":"Knobbe Martens","linkedin_profile":"https:\/\/www.linkedin.com\/in\/harnik-shukla-a9b45a8\/","biography":"
In the medical device field, I am routinely sought out for my technical expertise in electronics, sensors, waveforms and signal processing, and machine learning technologies. I am adept at transforming complex technical and legal analysis into pivot points for my clients to make a strategic decision.
I have been involved in the intellectual property strategy, IP due diligence, and\/or acquisition of several companies, including the following recent deals for:
Masimo (diligence on $1.1 billion acquisition of Sound United)
Cala Health (diligence for a $77 million financing round)
Nalu Medical (diligence for a $65 million financing round)
RefleXion Medical (diligence for a $80 million financing round)<\/p>","country":"us","companies":[],"created_at":"2024-06-13T17:51:11.000000Z"},{"id":235,"name":"Gina Melchner von Dydiowa","title":"Venture Partner","photo":{"id":476,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/476\/gina-melchner-nlc.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/476\/conversions\/gina-melchner-nlc-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/476\/conversions\/gina-melchner-nlc-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/476\/conversions\/gina-melchner-nlc-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"NLC Health Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/gina-melchner-von-dydiowa\/","biography":"
Focused on Venture Capital and Private Equity opportunities.<\/p>","country":"us","companies":[],"created_at":"2024-06-03T18:31:06.000000Z"},{"id":238,"name":"Amir Soltanianzadeh","title":"Managing Partner & Founder","photo":{"id":479,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/479\/amir-soltanianzadeh-solardis.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/479\/conversions\/amir-soltanianzadeh-solardis-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/479\/conversions\/amir-soltanianzadeh-solardis-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/479\/conversions\/amir-soltanianzadeh-solardis-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Solardis Health Ventures","linkedin_profile":"https:\/\/www.linkedin.com\/in\/amirsoltanianzadeh\/","biography":"
Originally trained as an engineer at Stanford University, Nicole has a career evenly weighted between operating roles and venture investing. She started her career with ACS\/Guidant as a process development intern and advanced through multiple R&D and management roles until her final position as Head of Marketing, Asia-Pac, based in Hong Kong. Then moving onto Abbott, Nicole led strategic market activities for Abbott’s OUS discrete glucose monitoring and continuous glucose monitoring brands, with a final role as the Founding Director of the Abbott Biotech Ventures team.
Nicole is passionate about healthtech investing and working with entrepreneurs to transform the delivery of healthcare by focusing on innovations at the intersection of biology & technology.<\/p>","country":"us","companies":[],"created_at":"2024-06-14T17:36:43.000000Z"},{"id":256,"name":"Guy Holden","title":"Associate","photo":{"id":511,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/511\/guy-holden-astorg.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/511\/conversions\/guy-holden-astorg-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/511\/conversions\/guy-holden-astorg-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/511\/conversions\/guy-holden-astorg-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Astorg","linkedin_profile":"https:\/\/www.linkedin.com\/in\/guy-holden-506096105\/","biography":"
Prior to this, Guy spent two years at EPIC Private Equity where he was an Investment Professional focused on buyout and special situation private equity investments in the UK.
Guy holds an MPhil in Management from the University of Cambridge and a BA (Hons) in Economics from Durham University.<\/p>","country":"gb","companies":[],"created_at":"2024-06-14T16:29:11.000000Z"},{"id":254,"name":"Charles Cornevin","title":"Principal","photo":{"id":509,"mime_type":"image\/jpeg","url_original":"https:\/\/d2gogik193ou5n.cloudfront.net\/509\/charles-cornevin-lauxera.jpg","url_small":"https:\/\/d2gogik193ou5n.cloudfront.net\/509\/conversions\/charles-cornevin-lauxera-small.webp","url_medium":"https:\/\/d2gogik193ou5n.cloudfront.net\/509\/conversions\/charles-cornevin-lauxera-medium.webp","url_large":"https:\/\/d2gogik193ou5n.cloudfront.net\/509\/conversions\/charles-cornevin-lauxera-large.webp"},"category":"investors_strategics","roles":["I"],"company_name":"Lauxera Capital Partners","linkedin_profile":"https:\/\/www.linkedin.com\/in\/charles-cornevin-4a526178\/","biography":"